CLSD

Clearside Biomedical, Inc. [CLSD] Stock Forecast

Q: What is Clearside Biomedical, Inc. stock symbol ?

Clearside Biomedical, Inc. is a US stock, located in Alpharetta of Ga and trading under the symbol CLSD

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CLSD Stock Summary

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Has a high level of debt. Debt-to-Equity ratio of 3.84 is considered high.

CLSD has less than 1 year of cash runway

Top 10 Correlated ETFs

CLSD

Top 10 Correlated Stocks

CLSD

In the News

08:22 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive Officer Charles Deignan - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Serge Belanger - Needham & Company Jonathan Wolleben - JMP Securities Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by and welcome to the Clearside Biomedical Fourth Quarter 2022 Financial Results and Corporate Update Conference Call.

07:49 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

04:41 26 Mar 2023 CLSD

Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Officer, Chief Development Officer Charles Deignan - Chief Financial Officer Dr. Arshad Khanani - Managing Partner at Sierra Eye Associates, Clinical Associate Professor at the University of Nevada Jenny Kobin - Investor Relations Conference Call Participants Andreas Argyrides - Wedbush Annabel Samimy - Stifel John Wolleben - JMP Securities Yi Chen - H.C. Wainwright Serge Belanger - Needham & Company Mayank Mamtani - B.

04:05 26 Mar 2023 CLSD

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022.

02:47 26 Mar 2023 CLSD

Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript

Clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciulla - Chief Medical Officer and Chief Development Officer Charles Deignan - CFO Conference Call Participants Stacy Lee - Stifel Rohit Bhasin - Needham & Company Yi Chen - H.C. Wainwright William Wood - B.

07:05 26 Mar 2023 CLSD

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following investor conferences in August 2022:

CLSD Financial details

Company Rating

Strong Buy

Market Cap

59.52M

Income

-32.95K

Revenue

731K

Book val./share

0.18

Cash/share

0.8

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 May 2023

P/E

-12.76

Forward P/E

PEG

P/S

2.59

P/B

3.15

P/C

1.21

P/FCF

-20.82

Quick Ratio

10.28

Current Ratio

10.54

Debt / Equity

3.84

LT Debt / Equity

0.09

EPS (TTM)

EPS next Y

EPS next Q

EPS this Y

-108.7%

EPS next Y

EPS next 5Y

EPS last 5Y

-81.71%

Revenue last 5Y

-100%

Revenue Q/Q

EPS Q/Q

-400%

SMA20

-23.66%

SMA50

-32.89%

SMA100

-8.26%

Inst Own

15.17%

Inst Trans

-4.99%

ROA

-8%

ROE

-16%

ROC

-0.07%

Gross Margin

98%

Oper. Margin

-16%

Profit Margin

-20%

Payout

Shs Outstand

61.36M

Shs Float

53.18M

Target Price

52W Range

0.93-2.54

52W High

52W Low

RSI

34.62

Rel Volume

0.31

Avg Volume

216.79K

Volume

67.91K

Perf Week

-1.02%

Perf Month

-28.68%

Perf Quarter

-14.16%

Perf Half Y

-15.65%

Beta

1.96387

Volatility

0.03%, 0.14%

Prev Close

-4.9%

Price

0.97

Change

-3.96%

CLSD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0.06	0.17	0.64	0
Net income per share	-2.69	-0.81	-0.39	0.01	0
Operating cash flow per share	-2.58	-0.71	-0.28	-0.23	0
Free cash flow per share	-2.58	-0.71	-0.28	-0.23	0
Cash per share	1.33	0.59	0.37	0.65	0.8
Book value per share	0.77	0.29	0.19	0.82	0.18
Tangible book value per share	0.77	0.29	0.19	0.82	0.18
Share holders equity per share	0.77	0.29	0.19	0.82	0.18
Interest debt per share	0.32	0.14	0.04	0.01	0.02
Market cap	32.88M	110.7M	127.43M	127.89M	67.43M
Enterprise value	34.82M	93.61M	112.12M	98.13M	20.46M
P/E ratio	-0.4	-3.6	-7	340.14	-2.05K
Price to sales ratio	1.1K	50.94	16.14	4.32	0
POCF ratio	-0.42	-4.09	-9.71	-11.92	-5.05K
PFCF ratio	-0.41	-4.09	-9.67	-11.92	-4.95K
P/B Ratio	1.39	9.92	14.54	3.37	6.36
PTB ratio	1.39	9.92	14.54	3.37	6.36
EV to sales	1.16K	43.08	14.2	3.32	0
Enterprise value over EBITDA	-0.42	-3.06	-6.22	177.13	-690.91
EV to operating cash flow	-0.44	-3.46	-8.55	-9.14	-1.53K
EV to free cash flow	-0.44	-3.46	-8.51	-9.14	-1.5K
Earnings yield	-2.52	-0.28	-0.14	0	0
Free cash flow yield	-2.41	-0.24	-0.1	-0.08	0
Debt to equity	0.87	1.4	1.2	0.13	3.84
Debt to assets	0.46	0.58	0.55	0.11	0.79
Net debt to EBITDA	-0.02	0.56	0.85	-53.72	1.59K
Current ratio	4.1	2.31	1.82	9.08	8.54
Interest coverage	0	0	0	0	-9.07
Income quality	0.96	0.88	0.72	-28.55	0.41
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	489.47	7.74	1.36	0.39	0
Research and developement to revenue	2.28K	7.21	1.91	0.63	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0.02
Capex to revenue	-2.93	-0.01	-0.01	0	0
Capex to depreciation	-0.47	-0.12	-0.31	0	-1.7
Stock based compensation to revenue	159.5	2.12	0.46	0.17	0
Graham number	6.83	2.3	1.29	0.39	0.05
ROIC	-3.92	1.54	1.04	0.03	0
Return on tangible assets	-1.88	-1.15	-0.94	0.01	0
Graham Net	0.66	0.18	0.14	0.71	0.13
Working capital	32.47M	14.32M	8.18M	37.5M	43.62M
Tangible asset value	23.62M	11.16M	8.76M	37.98M	10.61M
Net current asset value	22.44M	9.6M	7.56M	37.21M	8.71M
Invested capital	0.42	0.49	0.23	0.02	0.12
Average receivables	0	0	0	5M	5M
Average payables	6.13M	4.07M	1.64M	1.47M	995.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	123.42	0
Days payables outstanding	0	0	0	0	1.88M
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	2.96	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-3.51	-2.76	-2.08	0.01	0
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q4

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0.37	0.01	0.01	0	0
Net income per share	0.31	-0.13	-0.13	-0.13	0.39
Operating cash flow per share	0.08	0.06	-0.09	-0.1	0.13
Free cash flow per share	0.08	0.06	-0.09	-0.11	0.13
Cash per share	0.51	0.57	0.48	0.89	0.8
Book value per share	0.64	0.53	0.42	0.31	0.18
Tangible book value per share	0.64	0.53	0.42	0.31	0.18
Share holders equity per share	0.64	0.53	0.42	0.31	0.18
Interest debt per share	0.01	0.01	0.01	0.03	0
Market cap	164.09M	137.55M	88.42M	68.01M	67.43M
Enterprise value	134.33M	103.77M	59.89M	15.04M	20.46M
P/E ratio	2.19	-4.5	-2.83	-2.17	0.73
Price to sales ratio	7.53	396.39	230.26	0	0
POCF ratio	32.47	35.53	-16.24	-10.99	8.71
PFCF ratio	32.47	35.53	-16.24	-10.73	8.54
P/B Ratio	4.32	4.34	3.5	3.67	6.36
PTB ratio	4.32	4.34	3.5	3.67	6.36
EV to sales	6.16	299.04	155.96	0	0
Enterprise value over EBITDA	7.16	-13.66	-7.7	-2.32	0.94
EV to operating cash flow	26.58	26.81	-11	-2.43	2.64
EV to free cash flow	26.58	26.81	-11	-2.37	2.59
Earnings yield	0.11	-0.06	-0.09	-0.12	0.34
Free cash flow yield	0.03	0.03	-0.06	-0.09	0.12
Debt to equity	0.13	0.14	0.22	2	3.84
Debt to assets	0.11	0.12	0.18	0.67	0.79
Net debt to EBITDA	-1.59	4.45	3.67	8.16	-2.15
Current ratio	9.08	8.49	5.56	10.54	8.54
Interest coverage	0	0	0	-5.18	-17.14
Income quality	0.27	-0.51	0.7	0.79	0.33
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.14	9.96	7.27	0	0
Research and developement to revenue	0.18	13.07	14.14	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0.03	0.02
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	-3.97	-1.26
Stock based compensation to revenue	0.06	3.77	3.53	0	0
Graham number	2.12	1.23	1.11	0.95	1.24
ROIC	-0.99	0.22	0.26	0.13	-0.48
Return on tangible assets	0.44	-0.21	-0.25	-0.14	0.45
Graham Net	0.55	0.5	0.39	0.27	0.13
Working capital	37.5M	31.12M	24.6M	49.66M	43.62M
Tangible asset value	37.98M	31.7M	25.25M	18.55M	10.61M
Net current asset value	37.21M	30.92M	24.49M	17.72M	8.71M
Invested capital	0.02	0.02	0.02	0.02	0.12
Average receivables	5M	5M	61.5K	123K	61.5K
Average payables	858.5K	1.17M	2.02M	2.19M	1.39M
Average inventory	0	0	0	0	0
Days sales outstanding	41.29	0	28.83	0	0
Days payables outstanding	0	0	0	0	463.24K
Days of inventory on hand	0	0	0	0	0
Receivables turnover	2.18	0	3.12	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.49	-0.24	-0.31	-0.42	2.19
Capex per share	0	0	0	0	0

CLSD Frequently Asked Questions

What is Clearside Biomedical, Inc. stock symbol ?

Clearside Biomedical, Inc. is a US stock , located in Alpharetta of Ga and trading under the symbol CLSD

What is Clearside Biomedical, Inc. stock quote today ?

Clearside Biomedical, Inc. stock price is $0.97 today.

Is Clearside Biomedical, Inc. stock public?

Yes, Clearside Biomedical, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 216.79K
Market Capitalization 59.52M
Employee 34
CEO Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Headquarters Alpharetta,GA,US
IPO Date 2016-06-02
Website https://www.clearsidebio.com

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.